Nanomix Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NNMX research report →
Price Chart
About the company
Boston Therapeutics, Inc. focuses on the discovery, production, and commercialization of therapeutic drugs aimed at fulfilling critical unmet medical needs in the areas of diabetes and inflammatory diseases. The company's pipeline features BTI-320, a non-systemic, carbohydrate-based tablet currently in Phase II clinical trials, which is being developed to reduce post-meal blood glucose levels in patients with pre-diabetes and type 2 diabetes.
- CEO
- David Gerald Ludvigson
- IPO
- 2021
- Employees
- 30
- HQ
- Lawrence, MA, US
Get TickerSpark's AI analysis on NNMX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $9.80K
- P/E
- -0.67
- PEG
- -0.00
- P/S
- 0.63
- P/B
- -0.00
- EV/EBITDA
- -1.40
- Div Yield
- 0.00%
- Gross Margin
- -449.57%
- Op Margin
- -54609.50%
- Net Margin
- -79825.09%
- ROE
- 128.37%
- ROIC
- 475.90%
Latest fiscal year · YoY change
- Revenue
- $15.45K-89.1%
- Gross Profit
- $-69,458-190.0%
- Op Income
- $-8,437,168
- Net Income
- $-12,332,976-5.6%
- EPS
- $-0.00+100.0%
- OCF Growth
- +3.7%
- FCF Growth
- +8.1%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 0.36
- RSI (14)
- 52
- Avg Volume
- 25
No earnings-call transcripts are available for NNMX yet.
- Free Float
- 47.7%
- Shares Outstanding
- 49.00M
- Float Shares
- 23.35M
Buy/sell ratio 3.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 13, 22 | Hetterly Chris | other | 500,000 |
| Oct 11, 22 | SCHIFFMAN GREGORY T | other | 12,920 |
| Mar 2, 22 | SCHIFFMAN GREGORY T | other | 36,167 |
| Jun 4, 21 | SCHIFFMAN GREGORY T | other | 21,631,402 |
| Dec 9, 22 | GRUENER GARRETT | buy | 7,380 |
| Dec 9, 22 | GRUENER GARRETT | buy | 2,620 |
| Nov 28, 22 | GRUENER GARRETT | buy | 213,366 |
| Nov 10, 22 | GRUENER GARRETT | buy | 355,610 |
| Oct 11, 22 | GRUENER GARRETT | buy | 355,609 |
| Sep 9, 22 | GRUENER GARRETT | buy | 355,609 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NNMX coverage
Recent articles, reports, and earnings notes.
No research on NNMX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NNMX report →